Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Molecular Point of Care Diagnostic Tests Market Potential & Opportunities 2018 - ResearchAndMarkets.com

Research and Markets
Posted on: 26 Feb 18

The "The Market and Potential for Molecular Point of Care Diagnostic Tests" report has been added to ResearchAndMarkets.com's offering.

Among the various technologies and products of the global in vitro diagnostics (IVD) market, molecular diagnostics performed at the point of care or near the patient are regarded as a leading expansion market. Molecular point-of-care (POC) diagnostics are able to improve the sensitivity and specificity of existing near-patient and rapid tests, and also expand the diagnostic capabilities at points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world. Existing POC diagnostics range from urinalysis dipsticks performed in physician office laboratories (POLs) through rapid infectious disease tests used to quickly diagnose admitted patients.

Real-World Estimates and Reliable Forecasts

There have been many projections made about molecular point care. This report provides consensus market views and realistic estimates for this novel field, incorporating primary and secondary research, feedback from end users and reports from vendors. It also factors in tests already being used by laboratories at this time and how molecular POC has fared in displacing those markets.

The researchers have produced two definitive market studies of this market in 2013, prior to significant product development, and 2016 as the first products - Alere i, BioFire Film Array, Gene Expert Omni and cobas Liat appeared on the scene. Now, with more market track records and approvals, mPOC products competing with traditional systems, the researachers have updated their findings with the latest information. Who is leading? Where is investment in mPOC systems? Who has products in development? What companies are lagging? What can we expect in the future. This report answers these questions and more.

Profiled companies include those with clinical molecular diagnostic systems applicable to POC testing markets; molecular diagnostic systems applicable to hospital lab molecular testing; development-stage molecular diagnostic systems for decentralized testing; molecular diagnostic products for use primarily in emerging markets of the developing world and for field testing; companies with original equipment manufacturer (OEM) platforms and component technologies that could be featured in the molecular POC diagnostics market; and other companies that have been involved in molecular POC diagnostics through investment, collaborative research or technology development that could allow them to enter the market.

The market introduction of POC diagnostics or tests (POCTs) often follows a period of technological maturation or refinement of an existing laboratory diagnostic modality or platform. One of the major enabling technologies for POC testing with molecular diagnostics is real-time polymerase chain reaction (qPCR) testing that eliminated the need for post-amplification electrophoresis and integrated detection within the same instrument that performed amplification.

Advances and innovations in microfluidics; isothermal and other alternative amplification chemistries; test automation; primers and probes; and next-generation sequencing (NGS) methods have been the most significant to the development of decentralized molecular diagnostics. In many cases, these technologies work together to facilitate clinical molecular testing in an automated manner within a smaller device.

Key Topics Covered:

1. Executive Summary

  • Molecular Point-of-care Diagnostics Defined
  • Strengths and Weakness of Molecular Point-of-care Testing
  • Component Technologies of Molecular Point-of-care Diagnostics
  • Scope and Methodology
  • Size and Growth of the Market
  • Conclusions

2. What is Molecular Point-of-Care Diagnostics?

  • Advantages and Disadvantages of Molecular Point-of-care
  • Real-Time PCR (qPCR)
  • Point-of-care Diagnostics in Brief
  • Examples of POCT settings

3. Molecular POC Systems on the Market and in Development

  • Detection
  • Next-Generation Sequencing
  • Molecular Platforms and Products for Decentralized Testing
  • Major Testing Applications for Molecular POC Diagnostics
  • Urgent Care Clinics

4. Market Analysis

  • Size and Growth of the Market
  • Challenges for Molecular POC
  • Market Leaders
  • Market by Geography

5. Company Profiles

  • Ahram Biosystems
  • Akonni Biosystems
  • Alere (Abbott)
  • Analytik Jena
  • Atlas Genetics
  • Axxin
  • Becton, Dickinson and Company
  • Biocartis
  • bioMerieux
  • Canon Biomedical
  • Cepheid
  • Hain Lifescience
  • Illumina
  • Immunexpress
  • Mbio Diagnostics
  • Meridian Bioscience
  • Metaara Medical Technologies
  • Micronics (Sony)
  • Molbio
  • MP Biomedicals
  • Nanodetection Technology
  • NanoIVD
  • Optigene
  • Orion Diagnostica
  • PositiveID
  • Pretect
  • Qiagen
  • QuantumDX
  • Quidel
  • Rheonix
  • Roche Diagnostics
  • Spartan Bioscience
  • Stat-DX
  • Veredus Laboratories

For more information about this report visit https://www.researchandmarkets.com/research/rbg4lr/global_molecular?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005702/en/

Business Wire
www.businesswire.com

Last updated on: 26/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.